Treatment of human cancers with an inherent antigen-processing defect due to a loss of peptide transporters (TAP-1 and TAP-2) and/or MHC class I antigen expression remains a considerable challenge. There is now an increasing realization that tumor cells with down-regulated expression of TAP and/or MHC class I antigens display strong resistance to cytotoxic T lymphocyte (CTL)-mediated immune control, and often fail to respond to the conventional immunotherapeutic protocols based on active immunization with tumor-associated epitopes (TAE) or adoptive transfer of tumor-specific T cells. In the present study, we describe a novel approach based on immunization with either genetically modified tumor cells or naked DNA vectors encoding TAE fused to an endoplasmic reticulum (ER) signal sequence (ER-TAE) which affords protection against challenge by melanoma cells with down-regulated expression of TAP-1/2 and MHC class I antigens. In contrast, animals immunized with a vaccine based on TAE alone showed no protection against tumor challenge. Although MHC-peptide tetramer analysis showed a similar frequency of antigenspecific CTL in both ER-TAE-and TAE-immunized mice, functional analysis revealed that CTL activated following immunization with ER-TAE displayed significantly higher avidity for TAE when compared to animals immunized with the TAE alone. These observations provide a new strategy in anti-cancer vaccine design that allows activation of a highly effective and well-defined CTL response against tumors with down-regulated expression of TAP and MHC class I antigens.
Introduction
There is now considerable evidence to support the notion T cells fail to recognize tumor cells as efficient targets for lysis (reviewed in 4). Malignant melanoma is a classic example that CD8 ϩ T cells play an important role in the control of human cancers (1-3). This control is directed through of a human tumor that evades cytotoxic T lymphocyte (CTL) surveillance (5) (6) (7) . This resistance to immune surveillance is expression of tumor-associated antigens which are processed intracellularly and presented on the surface of the tumor cell not due to an obvious CTL dysfunction in these patients but has been attributed, in many cases, to the down-regulation in a manner similar to that seen in virus-infected normal cells (3) . Nevertheless, it is clear that in many instances CD8 ϩ of essential components of antigen processing in these tumor cells, such as peptide transporters (TAP-1 and TAP-2) and/ (referred to as growth medium). The B3 CTL clone was maintained in growth medium supplemented with recombinant or surface MHC class I antigen expression (5, 7) . More recent studies by Kageshita and colleagues have shown that TAP IL-2 (20 U/ml; Chiron, Emeryville, CA) and stimulated weekly with irradiated E.G7OVA cells. down-regulation plays an important role in the clinical course of malignant melanoma, probably by providing melanoma Analysis of surface MHC class I antigen expression on B16 cells with a mechanism to escape from CTL recognition during and E.G7OVA cells disease progression (8) . A similar antigen-processing defect has also been documented in other human cancers (9-12).
MHC class I antigen expression on B16 and E.G7OVA cells was analyzed by surface immunofluorescence labeling folMost of these studies have shown that loss of TAP and MHC class I antigen expression is more frequently seen in lowed by flow cytofluorometry (FACS). Cells were initially incubated with H-2K b antigen-specific mAb (20.8.4, 28.8.6 metastases than in primary lesions (7, 8, 12) .
Recently, immunotherapeutic protocols based on vaccinaand Y3), washed and further incubated with polyclonal affinitypurified FITC-conjugated goat anti-mouse Ig (Silenus, Meltion with autologous dendritic cells (DC) sensitized with tumorassociated epitopes (TAE) have been used for the treatment of bourne, Australia). Labeled cells were analyzed using the FACScan (Becton Dickinson, Mountain View, CA) and results metastatic human melanoma (13, 14) . Although these clinical trials demonstrated limited evidence of clinical regression of expressed as mean fluorescence intensity. In some experiments, surface MHC expression on B16 cells was also tumors, a large proportion of the patients showed a detectable immune response following DC-based vaccination. The lack analyzed following treatment with IFN-γ. For this treatment B16 cells were incubated with recombinant IFN-γ (200U/ml) of tumor regression in these patients was not due to an underlying immune dysfunction, but correlates with the posfor 48 h at 37°C. Following this incubation, cells were washed in growth medium and incubated with H-2K b antigen-specific sibility of immune escape by the tumor cells (15). Indeed, in vitro analyses of malignant melanoma cell lines and mAb, and analyzed using FACScan as described above. metastatic melanoma biopsies frequently show loss of TAP Analysis of antigen-processing genes in B16 cells and/or HLA expression (5, 6, 8, 15) . Alternative therapeutic approaches based on in vivo use of proinflammatory cytoExpression of peptide transporters (TAP-1 and TAP-2) and H-2K b genes in B16 and E.G7OVA cells was analyzed by RTkines, such as IFN, or transfection of wild-type TAP genes in tumor cells are limited in their practical applications. Previous PCR. Total RNA from B16 and E.G7OVA cells was isolated by using a single-step RNA isolation reagent (Advanced studies from our laboratory have shown that direct translocation of CTL epitopes into the endoplasmic reticulum (ER) Biotechnologies, London, UK) and mRNA was reverse transcribed with oligo(dT) primer. Semiquantitative PCR analysis lumen with the help of an ER translocation signal sequence can completely repair the antigen-processing defect in TAPof relative amounts of TAP-1, TAP-2 and H-2K b cDNA was performed using the sequence specific primers as follows: down-regulated Burkitt's lymphoma cells in vitro (9). If such an approach can restore the antigen presentation in vitro, is 5Ј-TCTCTACCTGGTTCTGGTTC-3Ј and 5Ј-AGCGTGTCACTA-ATGGACTC-3Ј for TAP-1, 5Ј-CGGGTCGTGTAATTGACATC-3Ј it possible that activation of the immune system following immunization with CTL epitopes fused to an ER signal and 5Ј-GCAGCAGGATATTGGCATTG-3Ј for TAP-2, and 5Ј-GCAATGAGCAGAGT TTCCGA-3Ј and 5Ј-TCTTCAGGTCTsequence will result in destruction of tumor cells and thus prevent tumor outgrowth in vivo? To examine this possibility, GCTGTGATG-3Ј for H-2K b . Amplified products were separated on 2% agarose gels and scanned densitometrically we have tested a novel approach based on immunization with genetically modified tumor cells or naked DNA vectors using ImageQuant software version 3.3 (Molecular Dynamics, Sunnyvale, CA). encoding TAE fused to an ER translocation signal sequence to determine whether such an approach can afford protection Construction and transfection of minigene DNA expression against challenge by antigen-processing-defective tumor vectors cells.
Five distinct expression plasmids were used in this study. One of these constructs encoded the full-length OVA gene, Methods while the other two constructs were designed to encode a minigene that included H-2K b antigen-restricted CTL epitopes Establishment and maintenance of cell lines from either OVA, SIINFEKL (referred to as pSIIN), or tyrosinaserelated protein (TRP)-2, VYDFFVWL (referred to as pTRP) B16-F10, a mouse melanoma cell line of H-2 b haplotype (ATCC, Rockville, MD) of C57BL/6J origin, was used in the (18). In addition, another two constructs expressed either SIINFEKL or VYDFFVWL fused to an ER translocation signal present study. In addition, EL4 (H-2 b ), a mouse thymoma cell line, and E.G7OVA cells which is a clone of EL4 stably sequence (referred to as pSIINER and pTRPER). This signal sequence is derived from the adenovirus E3/19 kDa protein transfected with chicken ovalbumin (OVA) cDNA (16) (a kind gift from Dr F. Carbone), were also used in this study. A CTL (19) . These expression plasmids were constructed by annealing the specific synthetic oligonucleotides followed by clone (B3) specific for the H-2K b antigen-restricted CTL epitope SIINFEKL from OVA (17) (a kind gift from extension with Klenow fragment, DNA polymerase I and dNTPs, and cloned into specific restriction sites of expression Dr F. Carbone) was used to assess the antigen-processing function in tumor cells. All tumor cell lines were maintained vectors as described earlier (9). The B16 cell line was electroporated at 280 mV, 960 µF in RPMI 1640 medium supplemented with 2 mM glutamine, 10% FCS and with or without 5ϫ10 -5 M 2-mercaptoethanol with 10 µg of the plasmid DNA (pSIIN and pSIINER) as described elsewhere (9). After 48 h, cells were resuspended for CTL activity over a range of peptide concentrations using a standard 51 Cr-release assay. in 20 ml of growth medium containing hygromycin B (400 µg/ ml; Sigma, St Louis, MO). Following 3 weeks of hygromycin selection, transfected cells were cloned by limiting dilution in
Results and discussion a 96-well plate. These clones were expanded and maintained in growth medium containing hygromycin B (400 µg/ml).
Expression and functional analysis of MHC class I antigenprocessing genes in B16 melanoma cells Immunization with genetically modified tumor cells or naked plasmid DNA
In the first set of experiments, the B16 cell line was analyzed for the expression of peptide transporter (TAP-1 and TAP-2) C57BL/6J mice were immunized s.c. with either 1ϫ10 5 1B) . These results strongly suggest that B16 B16.SIINER or OVA TCR transgenic mice (OT-1; generously cells might be defective in processing MHC class I antigenprovided by W. R. Heath, WEHI, Parkville, Australia) were restricted CTL epitopes endogenously. isolated, and OVA-specific CD8 T cells were detected using
In the next set of experiments we analyzed the implication H-2K b tetramers containing the OVA protein-derived peptide of loss of TAP and MHC class I gene expression on the SIINFEKL. MHC tetramers were produced as previously endogenous processing function of CTL epitopes in B16 described (20,21). Briefly, H-2K b containing the biotin-protein cells. B16 cells were transfected with expression vectors ligase-dependent biotinylation substrate sequence was encoding either the full-length OVA (referred to as B16.OVA) folded in the presence of human β 2 -microglobulin and the or a minigene sequence encoding the H-2K b antigen-SIINFEKL peptide. Biotinylation was performed with biotinrestricted CTL epitope (SIINFEKL) from OVA (referred to as protein ligase (Avidity, Denver, CO). Tetramers were then B16.SIIN). These transfectants were then exposed to the OVAproduced from biotinylated HPLC-purified monomers by addispecific CTL clone B3. Data presented in Fig. 1(C) shows tion of streptavidin-phycoerithrin (PE) (Molecular Probes, that although TAP ϩ E.G7OVA cells were efficiently recognized Eugene, OR). For tetramer staining, cells were incubated with by the B3 clone, none of the B16 transfectants (B16.OVA or TriColor-labeled anti-CD8 (Caltag, Burlingame, CA) and PE-B16.SIIN) were recognized by this CTL clone. The lack of labeled SIINFEKL tetramers (1:100 dilution) for 60 min at 4°C.
CTL lysis was not due to a defect in peptide binding by Following incubation, cells were washed twice with cold H-2K b molecules expressed by B16 cells, since exogenous growth medium and resuspended in PBS supplemented with sensitization with synthetic SIINFEKL peptide epitope induced 2% FCS. Relative fluorescence intensities were then measured strong lysis by the B3 clone (data not shown). More importwith a FACScan as described above and analyzed using antly, endogenous presentation of the SIINFEKL epitope CellQuest software.
by the B16 transfectants was completely restored following treatment with IFN-γ (Fig. 1C) . Taken together, these Functional analysis of antigen-specific CTL from immunized observations indicated that down-regulated expression of mice antigen-processing genes in B16 cells significantly blocked endogenous presentation of MHC class I-restricted CTL epiSplenocytes from immunized mice were harvested and plated at 4ϫ10 6 cells/well in a 24-well Linbro plate. Splenocytes topes and thus interferes with immune recognition by specific T cells. were stimulated with the appropriate CTL peptide epitope (10 µg/ml)-coated autologous γ-irradiated (2500 rad) lipopolyTo determine whether the peptide transport defect can be rectified in B16, the cells were transfected with an expression saccharide (LPS)-stimulated blasts at a responder to stimulator ratio of 5:1. After 5 days, cultures were assayed vector encoding the SIINFEKL epitope fused to an ER translo-epitopes (9). Consequently B16 transfectants were tested for susceptibility to the B3 clone in a standard CTL assay. B16 cells transfected with pSIINER (referred to as B16.SIINER) showed significant lysis by B3 clone (Fig. 1C ) and this lysis was not dependent on IFN-γ treatment as seen for B16.SIIN cells. Thus it seems that the TAP-down-regulated B16 cells are unable to transport sufficient levels of peptides into the ER unless TAP-independent mechanisms operate to directly translocate peptide epitopes into the ER compartment thereby restoring the presentation of MHC-peptide complexes at the surface of the cell.
Immunization with TAE fused to an ER signal sequence affords protection against B16 cells
Recent studies on human melanoma patients strongly argue that a functional MHC class I antigen-processing and -presentation defect is one mechanism by which malignant melanoma escapes immune recognition, and thus must be accounted for by future rational immunotherapies for human melanoma (5, 8, 15 Fig. 2A-C) . It is important to mention here challenged with TAP-down-regulated B16 cells. Data presented in Fig. 2 (D) clearly demonstrate that prior immunization with pTRPER afforded strong protection against B16 challenge, while animals immunized with plasmid alone or pTRP cation signal sequence (referred to as pSIINER). Earlier studies have shown that expression of peptide epitopes fused showed a significantly higher tumor load following challenge with live B16 cells. These results were also confirmed by with this signal sequence in TAP-down-regulated Burkitt's lymphoma cells can restore endogenous presentation of CTL immunization with another plasmid DNA encoding SIINER
Analysis of antigen-specific CTL from immunized mice
To investigate the potential mechanism of protection afforded by ER signal sequence-based immunization, we analyzed antigen-specific T cells from the different groups of immunized mice using two different methods. Firstly, splenocytes from B16-, B16.SIIN-and B16.SIINER-immunized mice were isolated and stained with H-2K b /SIINFEKL tetramers to assess the frequency of antigen-specific CTL precursors (CTLp).
Representative data based on this tetramer analysis is shown in Fig. 3 . Splenocytes from OT-1 mice, used as a positive control, showed strong staining and Ͼ76% of CD8 ϩ T cells were positive for SIINFEKL tetramer (Fig. 3A) . Although immunization with B16.SIIN and B16.SIINER resulted in a significant induction of tetramer-positive CD8 T cells, surprisingly, the overall numbers of SIINFEKL-specific CTL in these two groups were very similar ( Fig. 3C-H) . Indeed, tetramer analysis of splenocytes indicated that B16.SIIN-immunized mice had 8.52 Ϯ 0.20% CD8 ϩ T cells specific for the SIINFEKL peptide, while 8.35 Ϯ 0.91% CD8 ϩ T cells were specific for the SIINFEKL epitope in B16.SIINER-immunized mice. Furthermore, limiting dilution analysis based on 51 Cr-release assay of CTL recovered from B16.SIIN-and B16.SIINERimmunized mice also showed comparable numbers of CTLp in splenocytes (data not shown).
In the second set of experiments splenocytes from these mice were stimulated with irradiated autologous LPS blasts coated with saturating concentrations of the SIINFEKL peptide (10 µg/ml). Following a single round of stimulation, the lytic activity of these T cells against H2-K b -positive EL4 cells sensitized with varying concentrations of the synthetic peptide epitope SIINFEKL was determined. Representative data from one such experiment is shown in Fig. 4 . This analysis clearly showed that although CTL from both B16.SIIN-and such vaccination strategies might also contribute towards the selection of TAP-down-regulated tumors. Indeed, a recent study by Nestle and colleagues showed that defective loading of peptides in the ER and loss of MHC class I antigen expression were consistently detected in situ in metastases from non-responders to a DC vaccination protocol (15). These observations are further supported by an analysis of in vitro established human malignant melanoma cell lines which showed that Ͼ60% of these lines expressed low or undetectable levels of TAP-1 and/or TAP-2 and surface expression of MHC class I molecules (5, 8) .
In the present study we describe a novel vaccine strategy which is capable of restricting the outgrowth of not only the TAP ϩ but also TAP-down-regulated cancer cells in vivo. Data presented here clearly demonstrate that immunization with tumor-associated CTL epitope(s) fused to an ER translocation signal sequence is an extremely efficient method of inducing a strong immune response which affords protection from a challenge by TAP-down-regulated melanoma cells. Although the precise mechanism of protection is still unclear, in vitro analyses strongly suggest that T cells from animals immunized It is important to mention here that this hypothesis is also was used in the assay.
supported by earlier studies of Restifo and colleagues who also showed that CTL responses in mice immunized with CTL epitopes fused to an ER signal sequence are consistently enhanced and persist long term (22,23). We strongly believe two approaches might induce very strong CTL responses that the current anti-tumor vaccines which are designed to in vivo, their efficacy in the control of rapidly proliferating TAPnegative tumor cells may be significantly reduced. In fact, induce a quantitatively enhanced tumor-specific CTL 
